Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

Everyone is talking about or using weight loss products. So, the government pounces. A batch of 17 drugs are on a list of medications in a second round of

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population could be eligible to take them, and patients have to stay on the drugs to keep the weight off.